Drugmakers moved AI into enterprise systems and data exchanges while AI rules stayed in draft
Facing patent expiries and the cost of R&D, large drugmakers spent the second quarter buying late-stage assets for cash and buying AI as enterprise software and milestone-weighted options. Regulators built their own AI and data programs, and the FDA lost several of the officials who launched them.
Editorial snapshot: 31 July 2026
The central finding
AI in pharma became an enterprise and data-access commitment in Q2 2026, ahead of clinical evidence and binding rules. Until the FDA’s draft guidance and the EU’s draft Annex 22 are final, existing GxP rules on validation and change control govern how those deployments can be used.
What changed for AI in pharma and biotech in the second quarter
Drugmakers, regulators and investors each made larger AI commitments in the quarter. The clinical evidence and the rules behind those commitments moved more slowly.
Capability
AI moved into data access and real-time trial data
The FDA received and validated real-time signals from an AstraZeneca trial, and Lilly offered about 100 smaller biotechs models trained on decades of its research data in exchange for their own.
Capital
Isomorphic’s round dominated U.K. biotech venture funding as deal counts stayed low
Isomorphic Labs’ $2.1 billion Series B was about three-quarters of U.K. biotech venture funding in the quarter, while the 366 disclosed biotech venture rounds in the first half were near a decade low.
Adoption
Drugmakers bought AI at enterprise scale, without reported returns
Bristol Myers Squibb agreed to give more than 30,000 employees access to Claude, and Lilly had signed about 20 AI licensing deals by May. None of the quarter’s deals or deployments reported an effect on margin, price or capacity.
Accountability
FDA lost the officials behind its AI programs, and no AI rule became binding
The commissioner, the chief AI officer and the acting head of the drug center left in May, weeks after the FDA launched real-time clinical trials. The FDA’s AI guidance and the EU’s Annex 22 for manufacturing remained drafts.
Operating question
Which of your AI uses affect product quality, data integrity or patient safety, and can each be validated, version-locked and owned by a named person under the GxP rules that apply today?
What AI made practical in drug development this quarter
The quarter’s capability changes were organizational. Regulators began receiving trial data continuously, a drugmaker turned decades of research data into a shared model service, and another committed to one vendor’s models across research, manufacturing and commercial work. These announcements concerned data access and deployment; none reported a measured gain in molecular-design accuracy.
Clinical trials · Proof of concept
Trial data can reach the regulator as it is generated
The FDA said it received and validated real-time signals from AstraZeneca’s Phase 2 TRAVERSE trial in mantle cell lymphoma, carried by Paradigm Health’s platform. Amgen’s Phase 1b STREAM-SCLC trial in small-cell lung cancer is the second proof of concept, and a pilot for early-phase trials is planned.
Discovery · Operating program
Proprietary research data traded for model access
Lilly’s TuneLab gives about 100 smaller biotechs access to models trained on decades of Lilly research data, using federated learning, in exchange for their own data. Incyte supplies proprietary experimental data to Genesis’ GEMS platform for structure and property prediction under their expanded collaboration.
Enterprise · Announced May 20
One vendor’s models across the value chain
Bristol Myers Squibb plans to use Claude for target identification, clinical study reports, regulatory submissions, manufacturing root-cause analysis, CAPA (corrective and preventive action) documentation, data-driven batch release decisions and engagement with health care professionals, connected to institutional knowledge under governance and audit controls.
Safety science · Sandbox announced June 9
Predictive safety models under regulatory supervision
The MHRA’s AI sandbox will test up to five approaches that predict pharmacokinetics, toxicity, adverse reactions and effects across patient subgroups, partly to reduce reliance on animal testing. Partner work was scheduled to begin in summer 2026.
Frontier models · Monthly releases
Frontier models arrived monthly, and OpenAI’s flagship doubled in price
OpenAI released GPT-5.5 in April at twice its predecessor’s list price, and OpenRouter measured 49% to 92% higher effective cost for the same users. Anthropic released Claude Opus 4.8 on May 28 and Claude Fable 5 on June 9, and OpenAI previewed GPT-5.6 on June 26.
Cost and consequence
No drugmaker disclosed what its model contracts cost. For validated work, the cost that recurs is change: draft EU Annex 22 makes retesting the default after configuration changes, and the FDA’s draft guidance expects manufacturing models to be maintained through change management, so each model replacement repeats part of the validation work.
AI capital concentrated in one company while typical biotech rounds stayed small
Biotech venture dollars rose in the first half while the number of rounds stayed near a decade low, and one AI company shaped the quarterly totals it entered. Pharma’s own cash went to late-stage and China-originated assets, and discovery platforms were bought through milestone-weighted deals.
Disclosed transactions, Q2 2026
Isomorphic’s round and Incyte’s Genesis payment beside the quarter’s two largest acquisitions
Disclosed amounts in USD millions, April to June 2026. Acquisition amounts are upfront cash and equity; the instruments differ and are labeled.
AbbVie/Apogee
Acquisition — $10.9B
Announced within 14 days of GSK/Nuvalent.
GSK/Nuvalent
Acquisition — $10.6B
Isomorphic Labs
Series B — $2.1B
Led by Thrive Capital; no clinical program disclosed.
Incyte/Genesis
Collaboration upfront — $120M
$80 million cash and $40 million equity; up to $232 million in milestones per program, plus royalties.
J.P. Morgan and DealForma Q2 2026 report; Isomorphic Labs; Pharmaceutical Executive.
366
Disclosed biotech venture rounds, first half of 2026
Against 371 a year earlier and 663 in the first half of 2021; median round $23.7 million. BioCentury data.
7 of 14
Rounds of $200 million or more raised by biotechs that describe AI as core to their strategy
Those biotechs were about 24% of companies disclosing round sizes in the half. BioCentury data.
Median venture round by development stage, first half of 2026
Disclosed biopharma venture rounds compiled by DealForma for J.P. Morgan: $16.3 billion across 235 rounds in the half.
| Stage | Median round |
|---|---|
| Platform or discovery | Median round $22 million |
| Preclinical | Median round $29 million |
| Phase 1 | Median round $40 million |
| Phase 2 | Median round $63 million |
| Phase 3 | Median round $73 million |
Concentration
Isomorphic dominated the quarterly totals it entered
Its $2.1 billion round was £1.55 billion of the U.K.’s £2.05 billion in second-quarter biotech venture funding and 37% of CB Insights’ quarterly digital-health total. Without it, U.K. venture funding was £498 million, against £279 million a year earlier.
Measurement
Totals depend on what a tracker counts
DealForma counted $9.2 billion of biopharma venture funding in the quarter. TD Cowen’s tracker counted $34.3 billion raised by biotech companies, its best quarter in almost two years, in a total not broken out by financing type. DealForma’s figure covers venture rounds only.
Patent cliff
Pharma’s cash went to late-stage and China-originated assets
J.P. Morgan tied oncology licensing to “large pharma’s need to replace revenue caused by upcoming patent cliffs.” First-half licensing totaled $166.7 billion in deal value, about 6% of it upfront. China-originated assets made up 42% of large-cap licensing deals with at least $50 million upfront and 68% of those upfront dollars.
Deal structure
Discovery platforms are bought as options
Big pharma signed 41 platform and discovery in-licensing deals in the first half, at a median upfront of $62 million. Incyte’s expansion with Genesis follows the pattern: $120 million upfront against potential value of more than $1 billion across the first five targets, most of it contingent on milestones.
What it signals
Money for AI discovery arrived as a few very large rounds and milestone-heavy partnerships, while cash for clinical assets moved at far larger scale. For a typical discovery biotech, an AI strategy did not lift round size: median rounds rose with clinical stage, and AI-describing biotechs’ median trailed their peers’.
How drugmakers and regulators are sourcing AI work
Delivery moved in three directions. Pharma bought horizontal model capacity and pushed it into regulated workflows, a drugmaker became a platform supplier to smaller companies, and regulators built their own data pipes and review tools. Each puts integration with existing trial, laboratory and quality systems at the center of the work.
Build or buy
Three ways companies are sourcing AI
Bristol Myers Squibb bought enterprise access to one horizontal vendor, Anthropic. Lilly built infrastructure, including its LillyPod system of 1,016 NVIDIA Blackwell GPUs, and had signed about 20 AI technology licensing deals by May, the most of any drugmaker on UBS’s count. Recursion and Insilico keep discovery through clinical development in-house.
Platform model
A drugmaker as supplier to smaller biotechs
Lilly’s TuneLab trades model access for data, and Dave Ricks likened it to an app store for biotech scientists. Lilly announced on May 20 that TuneLab would be integrated into Collaborative Drug Discovery’s CDD Vault, and Charles River joined to provide nonclinical testing to participating companies.
Regulators
Regulators building their own systems
The FDA said it had consolidated 40 application intake systems, three data-monitoring systems and seven adverse-event reporting systems into one platform each, saving at least $120 million a year. It also said new models reach its staff in about a week and that it uses Gemini and Claude.
Programs launched or contracted in the quarter
| Program | Date | Status at June 30 | Disclosed terms or results |
|---|---|---|---|
| FDA real-time clinical trials | Date April 28 | Status at June 30 Two proof-of-concept trials; pilot planned | Disclosed terms or results Signals from one trial received and validated |
| FDA one-day inspection pilot | Date May 6 | Status at June 30 Runs through fiscal 2026 | Disclosed terms or results 46 one-day assessments; AI method undisclosed |
| Bristol Myers Squibb and Anthropic | Date May 20 | Status at June 30 Enterprise agreement announced | Disclosed terms or results No terms or outcomes disclosed |
| Lilly TuneLab in CDD Vault | Date May 20 | Status at June 30 Integration announced | Disclosed terms or results No terms disclosed |
| Incyte and Genesis | Date May 20 | Status at June 30 Expanded collaboration | Disclosed terms or results $120 million upfront Up to $232 million in milestones per program |
| MHRA AI sandbox | Date June 9 | Status at June 30 Announced; partner work from summer | Disclosed terms or results Up to five approaches; funding not stated |
Dates are 2026 announcement dates.
Integration
In each case the engineering work is integration: trial-site data capture, laboratory and quality systems, and regulatory document management. Bristol Myers Squibb described connecting Claude to knowledge held in disconnected systems but named no integrations, and none of these announcements reported an outcome.
Adoption by segment shows in contracts more than in surveys
Most of what can be observed about adoption in this industry is transactional: who signed what with whom, and how many people a deployment covers. Each row below uses its publisher’s own measure, so together they show the shape of adoption by segment rather than a single rate.
AI adoption signals by segment
Each row uses its publisher’s own measure and population; the rows are not comparable with one another.
| Signal | Segment | Value | Population and period |
|---|---|---|---|
| Biotechs describing AI as core to strategy | Segment Discovery-stage biotech | Value About 24% | Population and period First-half 2026 financings; BioCentury |
| Biotechs using Lilly’s TuneLab | Segment Discovery-stage biotech | Value About 100 | Population and period June 2026; Lilly via the Financial Times |
| Venture rounds to companies with a drug in human testing | Segment Clinical-stage companies | Value 42, about two-thirds | Population and period First half of 2026; BioPharma Dive tracker Companies backed by 26 tracked investors |
| AI technology licensing deals signed by Lilly | Segment Established pharma | Value About 20 | Population and period As of May 2026; Lilly and UBS via the Financial Times |
| Bristol Myers Squibb employees to receive Claude | Segment Established pharma | Value More than 30,000 | Population and period Announced May 20; deployment plan |
| Platform and discovery in-licensing deals by big pharma | Segment Established pharma | Value 41 | Population and period First half of 2026; DealForma Median upfront $62 million |
| FDA staff using generative AI | Segment U.S. regulator | Value More than 80% | Population and period April 2026; FDA officials Some centers above 90%; about 1% in early 2025 |
| AI use cases across the EU medicines regulatory network | Segment EU regulator | Value 61 | Population and period 2025; EMA AI Observatory |
Discovery-stage biotech
An AI strategy no longer sets a discovery biotech apart
AI has become common among financed biotechs without lifting the typical round. Incumbents now offer models trained on their own data in exchange for a biotech’s data, which makes data-sharing terms part of the price of model access.
Clinical-stage organizations
Clinical-stage companies drew most tracked venture rounds
About two-thirds of tracked first-half venture rounds went to companies with a drug in human testing; the count does not separate AI-derived programs. Sponsors entering the FDA’s real-time trial pilot would need endpoints and signals defined in advance and validated, near-real-time data flows from sites, and the program’s durability after the May departures is uncertain.
Established pharma
Large drugmakers moved from pilots to enterprise governance
Bristol Myers Squibb’s agreement spans GxP and non-GxP work, and Lilly expects 2026 R&D spending in the high teens of billions of dollars, up from $13 billion in 2025. The question has moved to governing one vendor’s models across regulated and unregulated functions, a line draft Annex 22 would sharpen.
Service and manufacturing partners
CROs, CDMOs and platforms as the integration layer
Charles River in TuneLab, Paradigm Health in the FDA’s real-time trials and CDD as a TuneLab host sit between AI platforms and wet-lab or clinical validation. Contract manufacturers running machine-learning models in critical GMP steps for sponsors would carry draft Annex 22’s obligations if it is adopted as drafted.
Economics
Contract values stayed private, and no deal or deployment reported an effect on margin, price or capacity. The public case for the spending rested on speed claims, such as the FDA’s 40% trial-time estimate and Recursion’s discovery timelines, rather than on reported returns.
Results from AI-derived drug programs remained early-stage
The quarter’s clinical results for AI-derived molecules came from company releases and sat early in development: a Phase 2 readout, early safety data, a first patient dosed and an investigational new drug (IND) clearance. The FDA’s process results were reported by officials without published methods.
Phase 2 · Company-reported
Recursion’s polyp-burden data for REC-4881
In familial adenomatous polyposis, 40% of patients improved in Spigelman stage, and 15.8% had Grade 3 treatment-related adverse events, with none higher. Recursion is discussing a registrational design with the FDA and expects to give an update in the second half of 2026.
Limitation: Measured against baseline; no control arm was stated.
−43%Median change in polyp burden, week 13
−53%Week 25, after a treatment break
Phase 1/2 · Company-reported
Early safety data for REC-1245
In the DAHLIA trial of Recursion’s RBM39 degrader, no patient had a dose-limiting toxicity and the maximum tolerated dose was not reached. Grade 3 treatment-related adverse events occurred in 6.2% of patients.
16Patients treated
62.5%Any treatment-related adverse event
Preclinical · Company comparison
Recursion’s discovery-speed claim
Recursion says REC-1245 reached development-candidate status more than twice as fast as the industry average, without disclosing the benchmark, and reports about 20 months for REC-4539, whose first trial patient was dosed in April.
18 monthsDiscovery to development candidate, REC-1245
IND · Company-reported
Insilico’s inhaled rentosertib cleared in China
Insilico announced on April 28 that China’s drug regulator had cleared its investigational new drug application for an inhaled form of rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis. The Phase 1 trial will test safety, tolerability and pharmacokinetics.
13thIND from Insilico’s AI-driven pipeline
About 80Planned Phase 1 participants
Process · Agency-reported
FDA’s administrative time claim
FDA officials said early generative AI pilots cut the time for some administrative tasks. No method or list of tasks was published with the claim.
10 days to 20 minutesSome administrative tasks in early pilots
Stage of evidence
Among these programs, the most advanced result was a company-reported Phase 2 readout measured against baseline. The results show AI-derived molecules producing ordinary early clinical data; they do not yet bear on whether AI improves success rates.
Four claims from the quarter and what the record supports
Each claim below circulated during the quarter or about it. The corrections change what a sponsor can plan on.
Trial duration · Official estimate
The 40% figure was an official’s estimate at a pilot launch, with no published analysis.
Claim under review: The FDA says real-time clinical trials will cut trial time by up to 40%.
The FDA’s chief AI officer, Jeremy Walsh, said real-time trials could cut up to 40% of trial time, and Commissioner Marty Makary said about 45% of the time from Phase 1 to submission is dead time. Neither figure came with a published analysis, and both men left the agency in May.
Regulation · Still in draft
No AI-specific rule for drug development became binding in the quarter.
Claim under review: Regulators have finalized rules for AI in drug development.
The FDA’s January 2025 draft guidance on AI to support regulatory decisions was still listed as a draft on May 1, 2026. The EU’s draft Annex 22 on AI in manufacturing had no finalization date at the Irish regulator’s May 12 briefing, and the FDA-EMA guiding principles of January 2026 are principles, not formal guidance.
Trial approvals · Misattributed
The measured gain came from 2023 process reforms, before AI tools were introduced.
Claim under review: The MHRA halved clinical trial approval times with AI.
The MHRA’s October 2025 release reported approval times falling from 91 to 41 days across 4,617 applications assessed between September 2023 and August 2024, under its 2023 risk-proportionate approach. Its text described AI tools as “now being introduced,” so the measured period predates them.
AI drug programs · Not disclosed
Isomorphic named no clinical program or trial timeline with its round.
Claim under review: Isomorphic Labs’ $2.1 billion round funds drugs already in human trials.
The May 12 announcement described advancing programs toward the clinic. A first-in-human target of the end of 2025 was revised in January to a Phase 1 start before the end of 2026, according to reports of Demis Hassabis’ remarks at Davos.
Where AI programs proved fragile in the quarter
The quarter’s visible failures were institutional: programs that depended on officials who left, a risk model whose workings were not disclosed, a model withdrawn days after release and a security weakness in agent tooling. In each case responsibility stays with the sponsor or manufacturer whose records the AI touches.
Incident · April and May
FDA’s AI programs lost the officials who launched them
Vinay Prasad, director of the biologics center, left in April. Commissioner Makary resigned May 12, and Tracy Beth Hoeg, acting director of the drug center, and chief AI officer Jeremy Walsh left in May, weeks after real-time trials launched. Mintz said the AI officer role “now seems rudderless,” and Skadden warned that informal policies could be reversed or challenged.
Risk · Pilot from May 6
An unexplained AI risk model now sets inspection depth
The FDA’s one-day inspection pilot uses AI to classify facilities as low-risk and had produced 46 one-day assessments; it runs through fiscal 2026. Skadden noted that the FDA has given little detail on how the classification works, so manufacturers cannot see what drives it.
Incident · June 12
A generally available model was withdrawn after three days
Anthropic disabled Claude Fable 5, generally available since June 9, and Claude Mythos 5 for all customers after a U.S. Commerce Department export-control directive barring foreign-national access. Greenberg Traurig advised checking model aliases, routing, fallback settings and deemed-export exposure. Under GMP-style change control, a forced switch to another model needs impact assessment and retesting.
Risk · Demonstrated attacks
Agents act on the content they can reach
Researchers demonstrated a design flaw in Model Context Protocol software development kits affecting an estimated 200,000 instances, and an injection technique that hijacked major coding agents with an 85% success rate in testing. Deployments that connect agents to institutional knowledge and run Claude Code, as Bristol Myers Squibb described, make text in tickets, logs and documents a possible instruction channel into systems holding GxP records.
Reading results
Recursion tied lower spending to data timing and portfolio reprioritization
Recursion’s first-quarter R&D expense fell to $87.9 million from $129.6 million, which it attributed mainly to the timing of Tempus data purchases and operating efficiencies; revenue fell to $6.5 million from $14.7 million. It tied lower operating cash use to efficiencies and a strategic reprioritization of its clinical portfolio, and lower administrative costs to lower salaries.
Who is accountable
Responsibility for validated outcomes stays with the sponsor or manufacturer, whatever happens to the FDA’s programs or a vendor’s model list. Model versions, fallbacks and agent permissions belong in the validation record alongside the data.
AI rules for drug development stayed in draft in the U.S., EU and U.K.
The FDA’s draft guidance, the FDA-EMA principles and draft Annex 22 share a risk-based logic built on context of use and human accountability, and none became binding in the quarter. The FDA ran its policy through press releases and pilots, the EMA documented practice, and the MHRA built a supervised test space. The enforceable constraint remained the existing GxP framework of validation, data integrity and change control.
United States · Draft since January 2025
FDA’s AI credibility framework is still a draft
The guidance covers AI that informs decisions on safety, effectiveness or quality from nonclinical work to manufacturing. It excludes drug discovery and operational uses, such as drafting submissions, that do not affect patient safety, drug quality or study reliability. Its seven steps run from the question of interest and context of use through model risk and a credibility plan to an adequacy determination.
United States · Comments closed June 29
Real-time trials are a pilot, not guidance
The FDA’s request for information on the pilot closed June 29 after an extension, with final selection criteria scheduled for July and selections for August. Skadden said the FDA may revert to requiring two pivotal trials in most cases, which would reverse the single-trial default announced in February.
European Union · Consultation closed Oct. 7, 2025
Draft Annex 22 would keep LLMs out of critical GMP use
In QbD Group’s reading of the July 2025 draft, machine-learning models used where product quality, data integrity or patient safety is at stake must be static and deterministic, and large language models are unsuitable. Test data must be independent of training data, acceptance criteria must be set before testing, and retesting is the default after changes.
European Union · Report posted June 4
The EMA documented AI use and pointed to existing GMP controls
The EMA’s 2025 AI Observatory said existing GMP guardrails already mitigate many general AI risks and listed what applicants are bringing next, including generative AI for drafting submissions, clinical-outcome prediction, digital endpoints and predictive stability modeling. It noted that the proposed European Biotech Act would require further AI guidance.
European Union · Pending at June 30
AI Act high-risk dates moved, pending final adoption
A provisional agreement on May 7 would move high-risk obligations for Annex III uses to Dec. 2, 2027, and for AI in products under sectoral laws such as the EU medical device regulations to Aug. 2, 2028. Parliament adopted it June 16; with Council adoption and publication pending, Aug. 2, 2026, remained the legal baseline at quarter end.
Scope: Most AI used in drug research is not high-risk under the Act; AI-enabled devices and diagnostics used in trials can be.
United Kingdom · Announced June 9
The MHRA opened a sandbox for predictive safety models
Developers of AI that predicts pharmacokinetics, toxicity and adverse reactions will work directly with the regulator from the summer. The industry body ABPI called it a possible step toward the safe harbor it has sought and asked for alignment with the U.K.’s Centres of Excellence in Regulatory Science and Innovation.
Dated and pending items, as scheduled at the end of June
| Item | Date | Jurisdiction | Status at June 30 |
|---|---|---|---|
| FDA real-time trial RFI comments | Date June 29, 2026 | Jurisdiction U.S. | Status at June 30 Closed after extension from May 29 |
| FDA real-time trial pilot selection criteria | Date July 2026 | Jurisdiction U.S. | Status at June 30 Scheduled in April |
| EU AI Act remaining obligations | Date Aug. 2, 2026 | Jurisdiction EU | Status at June 30 Legal baseline while the Omnibus is pending |
| FDA real-time trial pilot selections | Date August 2026 | Jurisdiction U.S. | Status at June 30 Scheduled in April |
| MHRA sandbox partner work begins | Date Summer 2026 | Jurisdiction U.K. | Status at June 30 Scheduled |
| FDA one-day inspection pilot ends | Date Sept. 30, 2026 | Jurisdiction U.S. | Status at June 30 Runs through fiscal 2026 |
| Final EU GMP Annex 22, Annex 11 and Chapter 4 | Date No date | Jurisdiction EU and PIC/S | Status at June 30 Not final at May 12 |
| Final FDA guidance on AI for drugs and biologics | Date No date | Jurisdiction U.S. | Status at June 30 Draft at May 1 |
| AI Act Annex III and Annex I high-risk obligations | Date Dec. 2, 2027, and Aug. 2, 2028 | Jurisdiction EU | Status at June 30 If the Omnibus is adopted |
| New EU pharmaceutical legislation applies | Date 2028 | Jurisdiction EU | Status at June 30 Agreed December 2025 |
What applies now
Until these drafts are final, AI in regulated work answers to existing GxP obligations for computerized-system validation, data integrity and change control. Draft Annex 22 shows where manufacturing expectations are heading: fixed, deterministic models, independent and access-logged test data, and defined human roles.
Where regulators, drugmakers, vendors and analysts agree and differ
Three positions recur across constituencies. Access to proprietary experimental data is the binding constraint, a view shared by Lilly’s Dave Ricks, Bristol Myers Squibb’s Greg Meyers and CDD’s Barry Bunin, and expressed in Incyte’s deal terms. Evidence standards must be set before AI predictions replace experiments, as the MHRA’s sandbox advisers and the draft rules hold. The disagreements mostly describe different segments: AI-native vendors describe platform-scale change, while Ricks, whose company owns wet labs and clinical capacity, says AI-made drugs are not yet a reality. On trial time, the FDA’s departed leaders located the delay in data latency between phases; Skadden and PitchBook located the near-term risk in regulatory instability.
Regulators
The FDA’s departed leaders framed AI as a fix for trial latency; U.K. and EU voices framed it around evidence standards.
Marty Makary
Commissioner, FDA (resigned May 12)
“For 60 years, we’ve been conducting clinical trials in the same way”
Said at the April 28 launch of real-time clinical trials; he resigned two weeks later.
Regulator · launch remarks
Kyle Diamantas
Acting Commissioner, FDA
Pledged to minimize political interference and to listen to career scientists.
A lawyer and former deputy commissioner for human foods, he took over after Makary’s resignation.
Regulator · as reported by Skadden
Lord Vallance
U.K. Science Minister
“Too many promising medicines fail late in development”
His case for the MHRA sandbox on predictive safety and pharmacokinetic models.
Government · MHRA release
Alastair Denniston
Chair, National Commission into the Regulation of AI in Healthcare
The sandbox should establish what good evidence looks like for AI that predicts drug safety and pharmacokinetics.
An NHS doctor; his position anchors the call for evidence standards before predictions replace experiments.
Independent commission · MHRA release
European Medicines Agency
EU regulator
“AI was moving from concept to practice”
The same report said existing GMP guardrails mitigate many general AI risks.
Regulator · 2025 AI Observatory
Drugmakers and buyers
The most active buyers describe data access as the constraint and are cautious about claims of autonomous drug discovery.
Dave Ricks
Chair and CEO, Eli Lilly
Doubts that AI companies are yet making drugs with computers and says AI drug discovery is in its infancy, while promoting TuneLab, which he likened to an app store for biotech scientists.
The quarter’s clearest reservation came from the most active pharma buyer of AI technology.
Incumbent · Financial Times interview
Greg Meyers
Executive Vice President and Chief Digital and Technology Officer, Bristol Myers Squibb
Says most enterprise AI stops at the chatbot; Bristol Myers Squibb’s agreement is meant to put Claude into workflows across functions, with governance and audit controls.
Contract terms were not disclosed.
Buyer · trade press reports
Amy McKee
Senior Vice President, Oncology, AstraZeneca
Wants trial data to move across the ecosystem as quickly as possible.
AstraZeneca’s TRAVERSE trial is one of the FDA’s two real-time proofs of concept.
Sponsor · reported remarks
AI vendors and platforms
Vendors describe scale and breadth; their statements are commercial positioning.
Demis Hassabis
CEO, Isomorphic Labs
“a massive vote of confidence from a diverse group of top-tier international investors”
His framing of the $2.1 billion round rested on investor breadth; the release named no clinical timeline.
Vendor · company release
Eric Kauderer-Abrams
Head of Life Sciences, Anthropic
Described Claude as a single intelligence layer for pharma companies.
The positioning behind the Bristol Myers Squibb agreement.
Vendor · trade press report
Barry Bunin
CEO, Collaborative Drug Discovery
Says the TuneLab model depends on collaboration that gives broad access to research data.
Lilly and CDD announced on May 20 that TuneLab would be integrated into CDD Vault.
Platform partner · trade press report
Analysts and advisers
Analysts locate the near-term risks in capital concentration and the durability of FDA policy.
Lindsay Martin
Biopharma Analyst, BioCentury
“three times as likely to top $200M”
Describing AI biotechs’ financings in the first half; her analysis also found their median round trailed non-AI peers’.
Independent analyst
Ben Zercher
Senior Analyst, PitchBook
Said venture investment stayed strong in the first half, but that turnover at the FDA created uncertainty that could lead some investors to wait before sizing their bets.
Speaking to BioPharma Dive about first-half venture funding, which held up despite a threatened U.S. crackdown on investment in Chinese drug assets.
Independent analyst · reported remarks
Rachel Turow
Skadden, Arps, Slate, Meagher & Flom
“current program materials are best read as indicative rather than authoritative”
Written after the May departures, about the FDA’s real-time trials and related programs; law firms advise sponsors on FDA strategy.
Law firm · client alert
Three decisions for pharma and biotech leaders
Chief scientific officer
Decide which proprietary data to trade for model access
TuneLab and the Incyte-Genesis deal both price model access in experimental data. The terms decide who learns from your results and whether a platform’s models improve on your data for others.
Which datasets are we willing to share, under what controls, and what would we gain that we cannot build ourselves?
Head of quality
Decide where probabilistic models may sit in GxP processes
Bristol Myers Squibb lists batch release and CAPA documentation among its Claude uses, while draft Annex 22 would keep large language models out of critical GMP applications. Classifying uses now limits rework if the draft is adopted as written.
Which planned AI uses affect product quality, data integrity or patient safety, and can each run on a fixed, validated model with a defined human decision-maker?
Head of clinical development
Decide whether to build real-time trial data flows without a stable FDA program
Taking part in the FDA’s pilot would require signals defined in advance and validated data flows from sites, and the officials behind it left in May. The same capability serves a sponsor’s own trial monitoring, whatever happens to the pilot.
Which of our trials would justify pre-specified real-time signals on their own merits?
Four actions for the second half of 2026
1
Map AI uses against draft Annex 22’s critical-use test
List every current and planned AI use in GMP work with its model type and the decision it informs. The result is a register that separates critical uses from support uses before the final text arrives.
Head of quality
2
Make model versions and fallbacks part of the validation record
For each validated workflow that calls an external model, record the pinned version, the approved fallback and the retest a switch triggers, and limit agents to the systems the task needs. The result is a documented response ready for the next withdrawal or injection finding.
Head of technology
3
Keep a dated AI regulatory calendar tied to submission plans
Track the FDA’s real-time trial criteria and selections, the AI Act Omnibus, Annex 22 and the FDA’s AI guidance as scheduled or pending items, and treat program materials as provisional until they become guidance. The result is a calendar showing which submissions depend on which drafts.
Regulatory affairs
4
Benchmark AI platform terms against the first half’s deals
Compare proposed discovery-platform deals with the 41 big-pharma deals at a $62 million median upfront and with Incyte’s milestone-heavy Genesis terms. The result is a term-sheet reference that separates upfront cash from contingent value.
Business development
References
This briefing covers April 1 through June 30, 2026. Sources published after June 30 are cited only for what they report about that period.
Regulators and agencies
- FDA Announces Major Steps to Implement Real-Time Clinical Trials — U.S. Food and Drug Administration, 2026-04-28
- FDA pilot of real-time clinical drug trials using cloud and AI (Government Executive) — Government Executive, 2026-04-29
- FDA announces efforts to advance real-time clinical trials — RAPS Regulatory Focus, 2026-04-29
- Artificial Intelligence for Drug Development — U.S. Food and Drug Administration (CDER), 2026-05-01
- Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (Draft Guidance) — U.S. Food and Drug Administration, 2025-01-06
- 2025 AI Observatory report (EMA/67888/2026) — European Medicines Agency, 2026-06-04
- MHRA launches AI sandbox to accelerate medicines development and improve safety — Medicines and Healthcare products Regulatory Agency (GOV.UK), 2026-06-09
- UK clinical trial approval times twice as fast with AI and reforms — Medicines and Healthcare products Regulatory Agency (GOV.UK), 2025-10-07
- HPRA General Regulatory Update (QP Forum 2026) — Health Products Regulatory Authority (slides hosted by Trinity College Dublin), 2026-05-12
Legal and regulatory analysis
- Inside the EudraLex Annex 22: What's New for AI in Pharma Manufacturing and Why These Revisions Matter — QbD Group, 2025-10-31
- FDA and EMA Provide Guiding Principles for AI in Drug Development — McGuireWoods, 2026-01-27
- EU legislators agree to delay for high-risk AI rules — Hogan Lovells, 2026-05-07
- Parliament adopts the AI Omnibus: Council sign-off is the last step — iubenda, 2026-06-19
- FDA Leadership Upheaval: What Comes Next? — Skadden, Arps, Slate, Meagher & Flom, 2026-06-23
- FDA Flux - June 2026 Newsletter — Mintz, 2026-06-17
Capital and deals
- Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine — Isomorphic Labs, 2026-05-12
- Demis Hassabis's Isomorphic Labs: $2.7B Raised, Trials Due This Year — StartupHub.ai, 2026-06-08
- Q2 2026 Biopharma Licensing and Venture Report — J.P. Morgan (DealForma data)
- Biotech drew more venture dollars in 1H26 as deal count stayed lean — BioCentury, 2026-07-17
- AI biotechs punched above their weight in 1H26 venture megarounds — BioCentury, 2026-07-31
- Biotech venture funding in the first half of 2026 (BioPharma Dive tracker) — BioPharma Dive, 2026-07-13
- Isomorphic megadeal lifts UK biotech funding to five-year high — European Biotechnology, 2026-07-20
- Quarterly Biotech Funding Continues Upward in Q2 of 2026, Trend with 4th Straight Quarter of Growth — SynBioBeta, 2026-07-15
- CB Insights Reports Q2 2026 Digital Health Funding Decline as AI Mega-Rounds Drive Larger Deal Sizes — HLTH, 2026-07-31
Companies and products
- Pharma Roundup: Bristol Myers Squibb strategic agreement with Anthropic; Incyte and Genesis expand strategic collaboration — Pharmaceutical Executive, 2026-05-20
- Anthropic and Bristol Myers Squibb Expand Enterprise AI Collaboration Across Drug Development and Operations — HLTH, 2026-05-21
- Lilly, BMS, Incyte strike deals to keep biopharma's AI integration rolling — BioSpace, 2026-05-21
- Eli Lilly deploys weight-loss cash on 'App Store' for scientists — Financial Times (republished by The Irish Times), 2026-06-25
- Lilly Expands AI Drug Discovery Push With 'App Store' Model For Biotech Scientists — Pulse 2.0, 2026-06-24
Clinical and research results
- Recursion Reports First Quarter Financial Results and Provides Business Update — Recursion Pharmaceuticals, 2026-05-06
- Insilico Medicine news release: China CDE IND clearance for rentosertib inhalation solution — Insilico Medicine (via EurekAlert!), 2026-04-28
Models and security
- GPT-5.5 cost analysis — OpenRouter, 2026-05-04
- Introducing Claude Opus 4.8 — Anthropic, 2026-05-28
- Claude Fable 5 and Claude Mythos 5 — Anthropic, 2026-06-09
- Previewing GPT-5.6 Sol — OpenAI, 2026-06-26
- AI Company Anthropic Suspends Access to Claude Fable 5, Claude Mythos 5 Following US Export Control Directive — Greenberg Traurig, 2026-06-17
- MCP Security Crisis: Systemic Design Flaws in AI Agent Infrastructure — Cloud Security Alliance, 2026-05-04
- Agentjacking: MCP Injection Hijacks AI Coding Agents — Cloud Security Alliance, 2026-06-12
Thoughtful engineering for what’s next.
Have a question about what this means for your team? Let’s talk it through.
Start a conversation